Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:45 UTC |
---|
HMDB ID | HMDB0014842 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Naltrexone |
---|
Description | Naltrexone, also known as vivitrol or PTI-555, belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene. Naltrexone is a drug which is used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. also used for the management of alcohol dependence in conjunction with a behavioural modification program. Naltrexone is a very strong basic compound (based on its pKa). In humans, naltrexone is involved in naltrexone action pathway. Naltrexone is a potentially toxic compound. |
---|
Structure | [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1 |
---|
Synonyms | Value | Source |
---|
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one | ChEBI | 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one | ChEBI | N-Cyclopropylmethyl-14-hydroxydihydromorphinone | ChEBI | N-Cyclopropylmethylnoroxymorphone | ChEBI | Vivitrol | Kegg | 17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6-one | Generator | 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one | Generator | PTI-555 | HMDB | Du pont brand OF naltrexone hydrochloride | HMDB | ReVia | HMDB | Schering plough brand OF naltrexone hydrochloride | HMDB | Antaxone | HMDB | Bristol-myers squibb brand OF naltrexone hydrochloride | HMDB | Lacer brand OF naltrexone hydrochloride | HMDB | Lamepro brand OF naltrexone hydrochloride | HMDB | Naltrexone hydrochloride | HMDB | Pharmazam brand OF naltrexone hydrochloride | HMDB | United drug brand OF naltrexone hydrochloride | HMDB | Celupan | HMDB | Nemexin | HMDB | Orphan brand OF naltrexone hydrochloride | HMDB | Schering-plough brand OF naltrexone hydrochloride | HMDB | Trexan | HMDB | Bristol myers squibb brand OF naltrexone hydrochloride | HMDB | Hydrochloride, naltrexone | HMDB | Nalorex | HMDB |
| Show more...
---|
Chemical Formula | C20H23NO4 |
---|
Average Molecular Weight | 341.4009 |
---|
Monoisotopic Molecular Weight | 341.162708229 |
---|
IUPAC Name | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one |
---|
Traditional Name | naltrexone |
---|
CAS Registry Number | 16590-41-3 |
---|
SMILES | [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O |
---|
InChI Identifier | InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1 |
---|
InChI Key | DQCKKXVULJGBQN-XFWGSAIBSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Phenanthrenes and derivatives |
---|
Sub Class | Not Available |
---|
Direct Parent | Phenanthrenes and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Phenanthrene
- Isoquinolone
- Tetralin
- Coumaran
- 1-hydroxy-2-unsubstituted benzenoid
- Alkyl aryl ether
- Aralkylamine
- Piperidine
- Cyclic alcohol
- Tertiary alcohol
- 1,2-aminoalcohol
- Ketone
- Tertiary aliphatic amine
- Tertiary amine
- Ether
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organic nitrogen compound
- Organopnictogen compound
- Carbonyl group
- Organooxygen compound
- Alcohol
- Organic oxygen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 169 - 170 °C; 274 - 276 °C (hydrochloride salt) | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 3.07 g/L | Not Available | LogP | 0.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Naltrexone,1TMS,isomer #1 | C[Si](C)(C)OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@]45C2=C1O[C@H]4C(=O)CC[C@@]35O | 2877.8 | Semi standard non polar | 33892256 | Naltrexone,1TMS,isomer #2 | C[Si](C)(C)O[C@@]12CCC(=O)[C@@H]3OC4=C(O)C=CC5=C4[C@@]31CCN(CC1CC1)[C@@H]2C5 | 2826.2 | Semi standard non polar | 33892256 | Naltrexone,1TMS,isomer #3 | C[Si](C)(C)OC1=C2OC3=C(O)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)CC1 | 2857.4 | Semi standard non polar | 33892256 | Naltrexone,1TMS,isomer #4 | C[Si](C)(C)OC1=CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 2837.9 | Semi standard non polar | 33892256 | Naltrexone,2TMS,isomer #1 | C[Si](C)(C)OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@]45C2=C1O[C@H]4C(=O)CC[C@@]35O[Si](C)(C)C | 2812.0 | Semi standard non polar | 33892256 | Naltrexone,2TMS,isomer #2 | C[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)CC1 | 2828.6 | Semi standard non polar | 33892256 | Naltrexone,2TMS,isomer #3 | C[Si](C)(C)OC1=CC[C@@]2(O)[C@H]3CC4=CC=C(O[Si](C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 2817.6 | Semi standard non polar | 33892256 | Naltrexone,2TMS,isomer #4 | C[Si](C)(C)OC1=C2OC3=C(O)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C)CC1 | 2774.8 | Semi standard non polar | 33892256 | Naltrexone,2TMS,isomer #5 | C[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 2755.9 | Semi standard non polar | 33892256 | Naltrexone,3TMS,isomer #1 | C[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C)CC1 | 2803.4 | Semi standard non polar | 33892256 | Naltrexone,3TMS,isomer #1 | C[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C)CC1 | 3018.0 | Standard non polar | 33892256 | Naltrexone,3TMS,isomer #1 | C[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C)CC1 | 3473.0 | Standard polar | 33892256 | Naltrexone,3TMS,isomer #2 | C[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C)[C@H]3CC4=CC=C(O[Si](C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 2813.9 | Semi standard non polar | 33892256 | Naltrexone,3TMS,isomer #2 | C[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C)[C@H]3CC4=CC=C(O[Si](C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 2990.1 | Standard non polar | 33892256 | Naltrexone,3TMS,isomer #2 | C[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C)[C@H]3CC4=CC=C(O[Si](C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3450.8 | Standard polar | 33892256 | Naltrexone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@]45C2=C1O[C@H]4C(=O)CC[C@@]35O | 3129.2 | Semi standard non polar | 33892256 | Naltrexone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@]12CCC(=O)[C@@H]3OC4=C(O)C=CC5=C4[C@@]31CCN(CC1CC1)[C@@H]2C5 | 3066.2 | Semi standard non polar | 33892256 | Naltrexone,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=C2OC3=C(O)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)CC1 | 3090.4 | Semi standard non polar | 33892256 | Naltrexone,1TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3062.8 | Semi standard non polar | 33892256 | Naltrexone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@]45C2=C1O[C@H]4C(=O)CC[C@@]35O[Si](C)(C)C(C)(C)C | 3284.9 | Semi standard non polar | 33892256 | Naltrexone,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C(C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)CC1 | 3304.0 | Semi standard non polar | 33892256 | Naltrexone,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(O)[C@H]3CC4=CC=C(O[Si](C)(C)C(C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3284.0 | Semi standard non polar | 33892256 | Naltrexone,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC1=C2OC3=C(O)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C(C)(C)C)CC1 | 3240.0 | Semi standard non polar | 33892256 | Naltrexone,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C(C)(C)C)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3221.9 | Semi standard non polar | 33892256 | Naltrexone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C(C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C(C)(C)C)CC1 | 3475.4 | Semi standard non polar | 33892256 | Naltrexone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C(C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C(C)(C)C)CC1 | 3632.8 | Standard non polar | 33892256 | Naltrexone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=C2OC3=C(O[Si](C)(C)C(C)(C)C)C=CC4=C3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O[Si](C)(C)C(C)(C)C)CC1 | 3718.9 | Standard polar | 33892256 | Naltrexone,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C(C)(C)C)[C@H]3CC4=CC=C(O[Si](C)(C)C(C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3489.9 | Semi standard non polar | 33892256 | Naltrexone,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C(C)(C)C)[C@H]3CC4=CC=C(O[Si](C)(C)C(C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3522.3 | Standard non polar | 33892256 | Naltrexone,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(O[Si](C)(C)C(C)(C)C)[C@H]3CC4=CC=C(O[Si](C)(C)C(C)(C)C)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5 | 3664.5 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Naltrexone GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4l-9032000000-f869731a6a6d2ba21fc9 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Naltrexone GC-MS (2 TMS) - 70eV, Positive | splash10-00bc-9601600000-928a74224d18c2ec3c94 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Naltrexone GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Naltrexone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Naltrexone GC-MS ("Naltrexone,2TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-00di-0009000000-e30316dd5784a7100d38 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-0006-0009000000-2218214724e56047d52b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-0006-0009000000-bb047c719f3429eb4410 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-00di-0049000000-de9a717563978f22f02f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-00xr-0191000000-d2f2ff1e4eb93db46b5e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-03di-1390000000-091705f6f42bc0f1c209 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-03di-1890000000-148c5608ef92c1dcaac4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-0006-0009000000-6df03abdbdb7461f2945 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-0006-0009000000-059b1dffee7ef15b9e95 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-00di-0049000000-a20ede951b350fa97a31 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-00xr-0191000000-8a66ac92b4a1eadcc405 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-03di-1490000000-0cfb621f77295ff438f2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-03di-1980000000-63edda852273619df16c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone LC-ESI-ITFT , positive-QTOF | splash10-00di-0009000000-59ab0ef68d6e13a7d085 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 60V, Positive-QTOF | splash10-00xr-0191000000-8a66ac92b4a1eadcc405 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 45V, Positive-QTOF | splash10-00di-0049000000-02654ed4a592aa3f1d77 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 35V, Positive-QTOF | splash10-00di-0009000000-5c4b68f88d13143d13c8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 75V, Positive-QTOF | splash10-03di-1490000000-0cfb621f77295ff438f2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 75V, Positive-QTOF | splash10-03di-1390000000-091705f6f42bc0f1c209 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 60V, Positive-QTOF | splash10-00xr-0191000000-d2f2ff1e4eb93db46b5e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 15V, Positive-QTOF | splash10-0006-0009000000-f50bcaa6a045618a3c7d | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 30V, Positive-QTOF | splash10-0006-0009000000-acc2906c5a3c9b639ba8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 45V, Positive-QTOF | splash10-00di-0049000000-70f2ceb5abb36fef0fe6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 30V, Positive-QTOF | splash10-0006-0009000000-c9c1b724011247195d89 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Naltrexone 35V, Positive-QTOF | splash10-00di-0009000000-cdd147bc699e82a0eabc | 2021-09-20 | HMDB team, MONA | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00704 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00704 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00704 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4514524 |
---|
KEGG Compound ID | C07253 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Naltrexone |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 5360515 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 7465 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Schmitz JM, Stotts AL, Rhoades HM, Grabowski J: Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001 Mar-Apr;26(2):167-80. [PubMed:11316375 ]
- Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R: Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism". Alcohol Clin Exp Res. 2008 Jan;32(1):85-91. Epub 2007 Dec 7. [PubMed:18070245 ]
- Ray LA, Chin PF, Miotto K: Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22. [PubMed:20201811 ]
|
---|